drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (CAR NK cell)
drug_description
Allogeneic NK-92 cell therapy engineered to express a PD-L1–targeting CAR and high-affinity CD16, enabling killing of PD-L1–positive tumor/immunosuppressive cells and ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic NK-92 cells engineered to express a PD-L1–targeting chimeric antigen receptor and high-affinity CD16 (FcγRIIIa), enabling direct killing of PD-L1–positive tumor and immunosuppressive cells and enhancing antibody-dependent cellular cytotoxicity (ADCC).
drug_name
PD-L1 t-haNK
nct_id_drug_ref
NCT06061809